GSK makes the argument to bring back the multiple myeloma medication Blenrep
GSK is building a case to bring back its cancer therapy, Blenrep. Study outcomes disclosed Sunday suggest that combining this therapy with two other key multiple myeloma drugs impeded disease progression more than using Takeda’s Velcade and the same drug cocktail